Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 10 versus QUILLIVANT XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 10 versus QUILLIVANT XR.
DYANAVEL XR 10 vs QUILLIVANT XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyanavel XR is a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic neurons.
Extended-release oral suspension formulation of methylphenidate, a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their synaptic concentrations. The exact therapeutic effect in ADHD is unknown but is thought to involve dopaminergic and noradrenergic pathways in the prefrontal cortex.
Recommended starting dose for adults is 10 mg orally once daily in the morning. May increase in increments of 5-10 mg at weekly intervals based on tolerability and response. Maximum recommended dose is 60 mg/day.
Initial: 25 mg orally once daily in the morning; may increase weekly in 25 mg increments based on tolerability and response. Maximum: 75 mg once daily.
None Documented
None Documented
12 hours (amphetamine); clinical context: extended-release profile allows once-daily dosing
Approximately 4 hours; extended-release formulation provides therapeutic levels for ~12 hours.
Renal (80-90% as unchanged drug); fecal (minor, 1-5%)
Primarily renal (approximately 60% as unchanged drug); fecal excretion accounts for <5%.
Category C
Category C
CNS Stimulant
CNS Stimulant